Skip to content

A Clinical Study To Evaluate The Efficacy And Safety Of Ashwagandha Caplet In Individuals Suffering From Stress And Anxiety Disorders

A Multicentric, Prospective, Double Blind, Randomised, Placebo Controlled Clinical Study To Evaluate The Efficacy And Safety Of Ashwagandha Caplet In Individual Suffering From Stress And Anxiety Disorders - HWC/MSCD/PP/046/2021

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043464
Enrollment
244
Registered
2022-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or non-pregnant / non-lactating female subjects between =18 to =69 years of age. 2. Individuals presenting with mild to moderate stress and anxiety disorders as per DSM-V-TR Diagnostic Criteria and fulfilling one or both of the following criteria: a. Score of 17-24 on the Hamilton – A Scale b. A score 14-26 on the Perceived Stress Scale (PSS) As per the ICD 10 they may include like generalized anxiety disorder, panic disorder, social phobia or social anxiety disorder, post traumatic disorder etc. Post Covid patients who recovered 1 month prior to screening can be enrolled in the study. 3. Body mass index between 16.5 to 30 kg/m2 4. Women of child-bearing potential willing to use an adequate method of contraception to avoid pregnancy throughout the study period 5. Willing to sign inform consent document and abide by the study procedures

Exclusion criteria

Exclusion criteria: 1. Subjects with other known Psychiatric or Neurological conditions like major depression, schizophrenia, mental retardation, psychosis, severe case of migraine or other headache, uncontrolled hypertension, or vestibular abnormalities or any other uncontrolled neurological diseases. 2. Have a significant and uncontrolled acute or chronic coexisting illness related to Cardiovascular, Respiratory Gastrointestinal, Immunological, Metabolic, Endocrinology specially Thyroid disorder, Neurological system or any other condition which in the Investigators judgement contraindicate entry into the study. 3.History of taking(within 4 weeks prior to screening) psychoactive medication (anxiolytics, sedatives, hypnotics, anti-psychotics, anti-depressants, anti-convulsant, antihypertensives, centrally acting corticosteroids, opioid pain relievers) hypnotics, narcotic analgesics, antidepressants, anticonvulsants, sedating H1 antihistamines, over-the-counter and prescriptions stimulants, decongestants, melatonin, drugs for oral alkalization, and all other drugs or supplements known to affect sleep cycle. However controlled case of hypertension with stable dosages medication can be enrolled in the study. 4.Subjects with lymphatic congestion during colds and flu, or symptoms of ama. 5.Any dietary supplements that the Investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results e.g. melatonin, omega-3 dietary supplements. 6.Recent within 4 weeks prior to screening or ongoing systemic antibiotic therapy during the study period. 7.Female patients with PCOD/PCOS 8.Herbal preparations or formulations containing Ashwagandha, ginseng, ginkgo biloba, St. John Wort, Brahmi, kava kava or related herbs. 9.History or present case of Alcohol or drug dependence or Smokers . 10.Self-declared illicit drug users including cannabis and cocaine. 11.Participation in another study with any investigational product within 60 days of screening. 12.Significant laboratory abnormality related to Hematologic or Biochemical parameters, which in opinion of Investigator may interfere in the compliance or interpretation of the study results.

Design outcomes

Primary

MeasureTime frame
? Comparison of mean change in Hamilton- A scale score, at the end of 8 weeks between the groups ? Comparison of mean change in Perceived Stress Scale (PSS) score at the end of 8 weeks between the groups.Timepoint: 8 weeks

Secondary

MeasureTime frame
? Comparison of mean change in GHQ (General Health Questionnaire) scoring at the end of 8 weeks between the groups. ? Comparison of Fatigue Assessment Score on the basis of evaluation on Fatigue Assessment Scale (FAS) ? Proportion withdrawing from trial because of adverse events (tolerability). ? Safety evaluation through Incidence of adverse events during the study period. ? Compliance of the subject to the study medication.Timepoint: 8 weeks

Countries

India

Contacts

Public ContactKavitha R

Himalaya Wellness Company

rajesh.kumawat@himalayawellness.com08067549899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026